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Background: The present study was designed to evaluate the extent to which pretreatment with 
microneedles can enhance skin permeation of nanoparticles in vitro and in vivo. Permeation 
of live bacteria, which are physically nanoparticles or microparticles, through mouse skin 
pretreated with microneedles was also studied to evaluate the potential risk of microbial 
infection.
Methods and results: It was found that pretreatment of mouse skin with microneedles 
allowed permeation of solid lipid nanoparticles, size 230 nm, with ovalbumin conjugated on 
their surface. Transcutaneous immunization in a mouse skin area pretreated with microneedles 
with ovalbumin nanoparticles induced a stronger antiovalbumin antibody response than using 
ovalbumin alone. The dose of ovalbumin antigen determined whether microneedle-mediated 
transcutaneous immunization with ovalbumin nanoparticles induced a stronger immune response 
than subcutaneous injection of the same ovalbumin nanoparticles. Microneedle treatment permit-
ted skin permeation of live Escherichia coli, but the extent of the permeation was not greater 
than that enabled by hypodermic injection.
Conclusion: Transcutaneous immunization on a microneedle-treated skin area with antigens 
carried by nanoparticles can potentially induce a strong immune response, and the risk of bacte-
rial infection associated with microneedle treatment is no greater than that with a hypodermic 
injection.
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Introduction
Microneedles have been researched extensively to improve intradermal or transdermal 
drug delivery.1–5 The feasibility of microneedle-mediated delivery of nanoparticles 
into or through the skin has also been confirmed.6,7 Initially, McAllister et al reported 
permeation of latex nanoparticles of up to 100 nm through human cadaver epidermis 
after the skin was treated with solid microneedles (150 µm long, base diameter 80 µm).6 
Coulman et al showed permeation of polystyrene nanoparticles (138 ± 25 nm) 
through the micropores created in human skin by microneedles 280 µm long with a 
base diameter of 200 µm.7 In contrast, Zhang et al did not observe any permeation of 
poly(lactic-co-glycolic) acid nanoparticles (166, 206, or 288 nm) through human skin 
pretreated with microneedles 200 µm long but did show penetration of nanoparticles 
into the epidermis and dermis.8
New-generation vaccines based on recombinant DNA technology generally need 
a vaccine adjuvant to be strongly immunogenic, and data from numerous studies 
have shown that many polymeric or solid lipid nanoparticles used as vaccine antigen International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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carriers have potent adjuvant activity.9 One of the attractive 
  applications of the combination of microneedle and nano-
particle technologies is in vaccine delivery.10 In fact, there 
have been significant and successful efforts to utilize solid 
microneedles coated with nanoparticle-based vaccine formu-
lations, mainly virus-like particles, to perform transcutaneous 
immunization in animal models and in clinical trials.10–25 
However, the feasibility of transcutaneous immunization 
by applying antigens carried by nanoparticles onto a skin 
area pretreated with microneedles has not been thoroughly 
  evaluated. Although application of a vaccine formulation 
onto the skin prior to or after the skin area is treated with 
microneedles is associated with the slight inconvenience 
of being a two-step process, it does have some advantages. 
For example, the dose of vaccines that can be applied is 
not as limited as when the vaccine is to be coated on solid 
microneedles, and coating of a vaccine onto microneedles on 
a mass production scale is still a topic of active research.26 
Recently, Bal et al showed that application of diphtheria 
  toxoid formulated into nanoparticles (211 ± 4 nm) prepared 
with N-trimethyl chitosan onto a mouse skin area pretreated 
with solid microneedles (300 µm long) induced an anti-
diphtheria toxoid antibody immune response. However, the 
response was not stronger than when the diphtheria toxoid 
was used alone.25 Interestingly, it was reported that the simple 
physical mixture of diphtheria toxoid with N-trimethyl chi-
tosan nanoparticles was more immunogenic than diphtheria 
toxoid alone.25 Therefore, there continues to be a need to 
test whether transcutaneous immunization onto a skin area 
pretreated with microneedles with an antigen carried by 
nanoparticles is more effective than with the antigen alone.
Previously, Sloat et al reported the engineering of solid 
lipid nanoparticles of 200 nm in size from lecithin/glyceryl 
monostearate-in-water emulsions.27,28 It was shown that sub-
cutaneous injection of protein antigens conjugated onto the 
nanoparticles induced strong functional antibody and cellular 
immune responses.27,29 In the present study, the antibody 
responses induced by ovalbumin nanoparticles or ovalbumin 
alone when applied onto a mouse skin area pretreated with 
microneedle rollers were evaluated and compared, using 
ovalbumin as a model antigen chemically conjugated onto 
nanoparticles (mean diameter 230 nm) and three different 
microneedle rollers with different-sized microneedles. Prior 
to an in vivo animal immunization study, permeation of the 
ovalbumin nanoparticles through mouse skin treated with 
microneedle rollers was evaluated in vitro. Microneedle 
rollers are commercially available and used for cosmetic 
(self-application) and clinical treatment of the skin. It has 
been shown that sequential insertion of microneedles on a 
microneedle roller requires less insertional force than inser-
tion of microneedles on a flat patch.2
Finally, a very important issue related to microneedle-
based drug delivery has been rarely studied, ie, the potential 
risk of bacterial or viral infection via micropores created by 
the microneedles. Bacteria and viruses are physically nanopar-
ticles or microparticles. Therefore, any micropores that allow 
the permeation of nanoparticles might also allow permeation 
of bacteria and viruses. It is generally assumed that the risk 
of infection associated with microneedle treatment is low, 
and many microneedle-related safety studies in clinical trials 
have focused on the degree of irritation and pain caused by 
the microneedles.30–33 The first study on the ability of microbes 
to traverse microneedle-induced micropores was reported by 
Donnelly et al, whereby permeation of microbes through por-
cine skin pretreated with a microneedle array (280 µm long, 
base diameter 250 µm) was confirmed in vitro.34 In the present 
study, an ex vivo model was designed to evaluate permeation 
of live bacteria through a mouse skin area pretreated with 
microneedles of different sizes. A nonpathogenic Escherichia 
coli DH5α strain was used for this study.
Materials and methods
Materials
Dermaroller® microneedle rollers were purchased from 
  Cynergy (Carson City, NV). Digital pictures of the 
microneedle roller are shown in Figures 1A and 1B. There 
are 192 needles in eight rows on each roller. Three different 
microneedle rollers were used. Dimensions of microneedles 
on the different rollers are shown in Figure 1C. Based on 
the size of the microneedles, the microneedle rollers were 
named as rollers with large (1000 µm long, base diameter 
80 µm), medium (500 µm long, base diameter 50 µm), and 
small (200 µm long, base diameter 20 µm) microneedles. 
Ovalbumin, fluorescein-5(6)-isothiocyanate, 2-iminothiolane 
(Traut’s reagent), 3,3’,5,5’-tetramethylbenzidine   solution, 
sodium bicarbonate, sodium carbonate, Tween 20, and 
phosphate-buffered saline were from Sigma-Aldrich 
(St Louis, MO). Lecithin (soy, refined) was from Alfa 
Aesar (Ward Hill, MA). Glyceryl monostearate was from 
Gattefosse Corporation (Paramus, NJ). The 1,2-dipalmitoyl-
sn-glycero-3-phosphoethanolamine-N-[4-(p-maleimidophyl)
butyramide] (DPPE-maleimide) and 1,2-dioleoyl-sn-glycero-
3-phosphoethanolamine-N-carboxyfluorescein (DOPE-
fluorescein) were from Avanti Polar Lipids (Alabaster, AL). 
Goat antimouse immunoglobulin G was from Southern 
  Biotechnology Associates Inc (Birmingham, AL).International Journal of Nanomedicine 2011:6
L = 200 µm, d = 20 µm (small)
L = 500 µm, d = 50 µm (medium)
L = 1000 µm, d = 80 µm (large)
A
B
C
~ 2 cm
Figure 1 (A, B) Digital photos of a Dermaroller® microneedle roller (1000 µm 
long, base diameter 80 µm). (C) Diagram of microneedles on the three different 
Dermaroller microneedle rollers used (not to scale).
Note: L indicates the length of the microneedles and d is the base diameter of the 
microneedles.
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Preparation of nanoparticles
Nanoparticles were prepared as previously described.27,28 
Briefly, soy lecithin 3.5 mg and glyceryl monostearate 0.5 mg 
were placed into a 7 mL glass vial. One milliliter of deionized 
filtrated (0.22 µm) water was added into the vial, followed 
by heating on a hot plate to 70–75°C, with stirring and 
brief intermittent periods of sonication (Ultrasonic Cleaner 
Model 150T, VWR International, West Chester, PA). Once 
a homogeneous milky slurry was formed, Tween 20 was 
added in a stepwise manner to a final concentration of 1% 
(v/v) to form an emulsion, which was then allowed to stay at 
room temperature while stirring to form nanoparticles. The 
endotoxin level in the nanoparticle preparation was estimated 
to be 0.18–0.57 EU/mL using a ToxinSensorTM chromogenic 
limulus amebocyte lysate endotoxin assay kit from GenScript 
(Piscataway, NJ).29 The size and zeta potential of the nano-
particles were determined using a Malvern Zetasizer® Nano 
ZS (Westborough, MA).
To prepare the maleimide nanoparticles, DPPE maleim-
ide, which has a reactive maleimide group, was included in 
the lipid mixture (5%, w/w).27,29 To label the nanoparticles 
fluorescently, DOPE-fluorescein (5%, m/m of total lipids) 
was included in the lecithin and glyceryl monostearate mix-
ture during nanoparticle preparation.27,29
conjugation of ovalbumin  
onto the nanoparticles
The conjugation of ovalbumin onto the nanoparticles was 
completed as previously described.27–29 Prior to conjuga-
tion, ovalbumin was thiolated using Traut’s reagent. Oval-
bumin was diluted in carbonate buffer (0.1 M, pH 9.6), 
followed by addition of Traut’s reagent (20× molar excess) 
and a 60-minute incubation at room temperature.   Thiolated 
  ovalbumin was desalted using a PD10 column (GE 
  Healthcare, Piscataway, NJ). To react the thiolated ovalbumin 
with the nanoparticles, 1 mL of freshly prepared maleimide 
nanoparticles were mixed with thiolated ovalbumin (10 mg) 
in phosphate-buffered saline (0.1 M, pH 7.4) and stirred 
under nitrogen gas for 12 to 14 hours at room temperature. 
  Unconjugated ovalbumin was removed by repeated ultra-
centrifugation (600,000 × g) and washing with phosphate-
  buffered saline three times. The amount of ovalbumin 
conjugated onto the nanoparticles was estimated as previ-
ously described using fluorescein-labeled ovalbumin.27,29 
Ovalbumin was labeled with fluorescein following the manu-
facturer’s instructions (Promega Corporation, Madison, WI) 
before being conjugated onto the nanoparticles.
Permeation of ovalbumin and ovalbumin 
nanoparticles through microneedle- 
treated skin
An in vitro permeation assay using Franz diffusion cells 
was completed as previously described.6 The lower dorsal 
skin of C57BL/6 mice was used in all permeation stud-
ies. Hair was trimmed using an electric clipper 24 hours 
before collection of the skin, which was stored at -20°C 
for a maximum period of one month and used when 
needed. After the fat layer was carefully removed, the 
skin was placed onto the flat surface of a balance, and 
the microneedle rollers were rolled in four perpendicular 
lines over the skin surface, five times each for a total of 20 
times, with an applying pressure of 350 to 400 g, which 
was constantly measured using the balance while rolling 
the microneedle roller.35 The skin was then mounted onto 
Franz diffusion cells from PermeGear Inc (Hellertown, PA), 
dorsal side facing upward. The receiver compartment con-
tained 5 mL of phosphate-buffered saline (pH 7.4, 10 mM) 
and was maintained at 37°C with a Haake SC 100 water 
circulator from ThermoScientific (Wellington, NH). The 
diffusion area of the skin was 0.64 cm2. The donor com-
partment was loaded with fluorescein-labeled ovalbumin or 
  fluorescein-ovalbumin nanoparticles in phosphate-buffered 
saline (500 µL, pH 7.4, 10 mM) and covered with parafilm 
to prevent evaporation. The amount of ovalbumin protein 
loaded into the donor compartment was 0.6 mg. At hours 
0, 1, 2, 4, 8, and 24, 200 µL samples were withdrawn from 
the receiver compartment and immediately replenished with 
fresh phosphate-buffered saline. The fluorescence intensity 
in the sample was measured using a BioTek SynergyTM HT 
multimode microplate reader (Winooski, VT).International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Methylene blue staining for visualization 
of micropores
Hair on the dorsal skin of C57BL/6 mice was trimmed before 
the mice were euthanized to remove the skin. The skin sample 
was treated with Nair® lotion (Church and Dwight Co, Princ-
eton, NJ), rinsed with water, paper dried, and placed onto 
the flat surface of a balance. Microneedle rollers were rolled 
once over the skin surface with an applying pressure of 350 to 
400 g. The skin was then stained with 20 µL of methylene blue 
solution for no more than five minutes, followed by removal 
of excessive stain using normal saline swabs and later alcohol 
swabs. Stained skin was visualized using a Stereoscopic Zoom 
Nikon SMZ1500 microscope (Melville, NY). As a control, 
skin was also punctured with a 21 gauge hypodermic needle 
(Becton Dickinson, Franklin Lakes, NJ).
Immunization studies
All animal studies were carried out following the National 
Institutes of Health guidelines for animal care and use. The 
animal protocol was approved by the Institutional Animal 
Care and Use Committee at The University of Texas at 
  Austin. Female C57BL/6 mice (18–20 g) were used for the 
immunization studies. Twenty-four hours prior to the applica-
tion of the vaccine formulations, hair on the dorsal side of 
the mice was carefully trimmed. The skin was cleaned with 
an alcohol swab, and a 2 cm2 area was marked on the skin 
surface. Mice were anesthetized and placed onto the flat 
surface of a balance to monitor the pressure applied during 
application of the microneedle rollers. The microneedle 
rollers were disinfected with ethanol 70% and then rolled in 
two perpendicular lines over the lower dorsal marked skin 
surface, ten times each, again for a total of 20 times,5 with an 
applying pressure of 350 to 400 g. Ovalbumin in phosphate-
buffered saline or ovalbumin-conjugated nanoparticles in 
phosphate-buffered saline were carefully dripped onto the 
treated area; the skin area was then covered with a piece of 
self-adhesive Tegaderm® patch (3M, St Paul, MN), which was 
carefully removed 24 hours later. Immunization was repeated 
10 days apart on two further occasions. As a positive control, a 
group of mice were subcutaneously injected three times with 
ovalbumin-conjugated nanoparticles in phosphate-buffered 
saline. Two weeks (or as where mentioned) after the last 
immunization, mice were bled for antibody assay. The dose 
of ovalbumin was 10.5 µg or 70 µg per mouse.
enzyme-linked immunosorbent assay
An enzyme-linked immunosorbent assay was completed as 
previously described.27,28 Briefly, EIA/RIA flat-bottomed, 
medium-binding, 96-well polystyrene plates (Corning 
Costar, Corning, NY) were coated with 100 ng of ovalbumin 
in 100 µL of carbonate buffer (10 mM, pH 9.6) overnight 
at 4°C. Plates were washed with phosphate-buffered saline/
Tween 20 (10 mM, pH 7.4, 0.05% Tween 20, Sigma-Aldrich) 
and blocked with 5% (v/v) horse serum in phosphate-
buffered saline/Tween 20 for one hour at 37°C. Samples 
were diluted 10-fold serially in 5% (v/v) horse serum in 
phosphate-buffered saline/Tween 20, added to the plates 
following the removal of the blocking solution, and incu-
bated for a further two hours at 37°C. The serum samples 
were removed, and the plates were washed five times with 
phosphate-buffered saline/Tween 20. Horseradish peroxi-
dase-labeled goat antimouse immunoglobulin G (5000-fold 
dilution in 1.25% (v/v) horse serum in phosphate-buffered 
saline/Tween 20) was added into the plates, followed by 
another hour of incubation at 37°C. Plates were again 
washed five times with phosphate-buffered saline/Tween 
20. The presence of bound antibody was detected following 
incubation for 30 minutes at room temperature in the pres-
ence of 3,3’,5,5’-tetramethylbenzidine solution, followed 
by addition of 0.2 M sulfuric acid as the stop solution. The 
absorbance was read at 450 nm using a BioTek SynergyTM 
HT multimode microplate reader.
Transepidermal water loss
Mice were anesthetized, and hair on the lower dorsal skin 
was trimmed. Twenty-four hours later, the trimmed area 
was disinfected with ethanol 70% and treated with the 
microneedle rollers as mentioned earlier. Negative control 
mice received hair trimming only. Before and immediately 
after the needle treatment (0 hour), transepidermal water loss 
was measured using a VapoMeter from Delfin Technologies 
Inc (Stamford, CT) following the manufacturer’s   instructions. 
At least three readings were taken at every time point. If 
there were any uncharacteristic spikes during this period, a 
more representative reading was used.   Transepidermal water 
loss readings were also recorded at hours 2, 3, 4, and 24. For 
mice treated with the large microneedle roller, transepider-
mal water loss readings were also recorded 48 hours after 
treatment. The experiment was repeated using at least four 
mice per group.
In vitro permeation of bacteria  
through microneedle-treated skin
Hair-trimmed mice were treated with the microneedle rollers 
on the lower dorsal skin (10 times each in two perpendicular 
directions, for a total of 20 times) and then immediately International Journal of Nanomedicine 2011:6
AB
CD
Figure 2 Magnified microscopic view of mouse skin after treatment with a 21 gauge 
hypodermic needle (A) or microneedle rollers with different size microneedles, ie, small 
(B), medium (C), and large (D). The skin was stained with methylene blue solution.
Notes: The distance between the bars in A is 1 mm; all photos were taken under 
the same magnification.
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euthanized. The skin in the treated area was collected and 
used to evaluate the permeation of live bacteria on the same 
day. As controls, intact skin (hair trimmed) or skin punctured 
once with a 21 gauge needle were also used. In addition, 
for the microneedle roller with large microneedles, mice 
were treated with the roller and euthanized immediately or 
at hours 1, 3, 6, or 24 to collect the skin in the treated area. 
The collected skin was mounted onto Franz diffusion cells to 
evaluate the microbial permeation. Mouse skin in the treated 
area and the working surface in a laminar flow cabinet were 
disinfected with ethanol 70% before treatment. All dissecting 
tools were autoclaved before use.
E. coli DH5α bacteria were used to evaluate permeation 
of live bacteria through the treated skin. Bacteria were grown 
in Luria-Bertani medium (Sigma-Aldrich), harvested, and 
resuspended into the same volume of sterile phosphate-
buffered saline (pH 7.4, 10 mM). The OD600 value of the 
suspension was determined to be 1.27 ± 0.11. The bacterial 
suspension was diluted in sterile phosphate-buffered saline 
(pH 7.4, 10 mM) to 1000-fold, and 500 µL was then placed 
into the donor compartment of the diffusion cells. Four hours 
later, the sample in the receiver compartment was withdrawn, 
diluted 1-fold, 10-fold, and 100-fold in sterile phosphate-
buffered saline, and 50 µL was then spread onto Luria-Bertani 
agar plates, which were incubated at 37°C overnight to count 
the number of colonies formed. The number of bacteria dif-
fused through the skin was reported as colony forming units, 
and it was assumed that each colony had developed from a 
single bacterial cell. The diffusion cells and the parafilm 
used to cover the cells were thoroughly disinfected with 
ethanol 70% three times before use, and all other items were 
autoclaved before use.
statistical analysis
Statistical analyses were performed using analysis of variance 
followed by Fisher’s protected least significant difference 
procedure. A P value of #0.05 (two-tailed) was considered 
statistically significant.
Results and discussion
The ovalbumin nanoparticles were 230 ± 22 nm in diam-
eter, with a polydispersity index of 0.2. Their zeta potential 
was –31 ± 1 mV. The amount of ovalbumin conjugated 
onto the nanoparticles was determined to be 96.6 ± 11.0 µg 
ovalbumin per mg of nanoparticles.29 Lower dorsal mouse 
skin samples were harvested, treated with microneedle 
rollers, and used to evaluate permeation of the ovalbumin 
nanoparticles. Microscopic pictures of the skin stained with 
methylene blue solution immediately following treatment 
with different microneedle rollers are shown in Figure 2. As 
a control, the picture of the skin punctured by a 21 gauge 
hypodermic needle is also shown (Figure 2A). The single 
pore created by the hypodermic needle was about 1 mm in 
diameter, which is to be expected because the nominal outer 
diameter of a 21 gauge needle is 819.2 µm. The pores created 
by the microneedles were much smaller, and it seemed that 
the diameter of the micropores created using a roller with 
larger microneedles tended to be larger than that created using 
a roller with smaller microneedles (Figure 2), in agreement 
with what was previously reported by Zhou et al,5 who used 
ZTGSTM microneedle rollers. Due to the extensive diffusion 
of the blue dye, an accurate measurement of the diameters 
of those micropores was not attempted.
As shown in Figures 3A and 3B, neither ovalbumin 
protein in solution nor ovalbumin conjugated onto nanopar-
ticles could permeate through the intact skin, demonstrat-
ing the physical integrity of the skin samples. In contrast, 
both ovalbumin and ovalbumin nanoparticles were able to 
permeate through skin pretreated with microneedle rollers 
(Figures 3A and 3B). Moreover, pretreatment using a roller 
with larger microneedles allowed more extensive permeation 
than treatment using a roller with smaller microneedles. For 
example, within 24 hours, only a minimum amount of oval-
bumin nanoparticles permeated through the skin pretreated 
using a roller with small microneedles (200 µm long, base 
diameter 20 µm), whereas 13.6 ± 2.4% of the ovalbumin 
nanoparticles permeated through the skin treated with the 
roller with large microneedles (1000 µm long, base diameter International Journal of Nanomedicine 2011:6
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Figure 3 Permeation of fluorescein-labeled ovalbumin nanoparticles (A), fluorescein-labeled ovalbumin (B), or fluorescein-labeled ovalbumin-free nanoparticles (C) through 
mouse skin treated with different microneedles (small 200 µm, medium 500 µm, and large 1000 µm).
Note: Data shown are mean ± standard error (n = 5–7).
Abbreviations: MN, microneedle; OVA, ovalbumin; NPs, nanoparticles; FITC, fluorescein-5(6)-isothiocyanate.
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of 80 µm, Figure 3A). As expected, pretreatment with the 
microneedle rollers allowed more extensive permeation of 
the ovalbumin in solution than the ovalbumin conjugated 
onto nanoparticles (Figure 3A and 3B), considering that the 
ovalbumin nanoparticles are much larger than the ovalbumin 
molecules. For example, within 24 hours, 28.3 ± 6.5% of the 
ovalbumin in solution diffused through the pores created by 
the roller with large microneedles, which is significantly 
higher than the 13.6 ± 2.4% for the ovalbumin nanoparticles. 
To confirm that it was the ovalbumin nanoparticles, rather 
than the ovalbumin protein hydrolyzed from the ovalbumin 
nanoparticles, that diffused through the pores created by the 
microneedle rollers, permeation of the fluorescein-labeled 
nanoparticles alone was also monitored. As shown in 
  Figure 3C, the rate of diffusion of the fluorescein nanopar-
ticles was similar to the diffusion of the fluorescein-labeled 
ovalbumin nanoparticles. Finally, diffusion of DOPE-
fluorescein from the fluorescein-labeled nanoparticles 
placed into a dialysis tube (molecular weight cut off, 50,000) 
was evaluated as well. It was found that, within 24 hours, 
release of DOPE-fluorescein from the nanoparticles was 
not detectable, regardless of whether the release medium 
was phosphate-buffered saline or phosphate-buffered saline 
with sodium dodecyl sulfate 0.5% (data not shown), which 
indicated that the observed permeation of fluorescein-labeled 
nanoparticles in Figure 3C was not caused by the diffusion of 
the DOPE-fluorescein molecules from the fluorescein-labeled 
nanoparticles and then through the skin.
Taken together, the data in Figure 3 demonstrate that oval-
bumin nanoparticles of 230 ± 22 nm permeated through the 
micropores created by a microneedle, even using the roller with 
the smallest microneedles (200 µm long, base diameter 20 µm), 
and that as expected, the extent of permeation was dependent 
on the size of the microneedles used. This observation is in 
agreement with that of Coulman et al who showed permeation 
of 138 ± 22 nm polystyrene nanoparticles through human skin 
pretreated with microneedles (280 µm long, base diameter 
200 µm),7 but is in disagreement with the reports by Zhang et al 
and Bal et al using poly(lactic-co-glycolic) acid nanoparticles 
(166, 206, or 288 nm) and diphtheria toxoid-N-trimethyl chito-
san nanoparticles (211 ± 4 nm), respectively.8,25 In the study by 
Bal et al, the length of microneedles used was 300 µm.25 The 
size of the nanoparticles used in the present study was similar to 
that used by Bal et al. It is interesting that the ovalbumin nano-
particles permeated through the skin area pretreated with the 
smallest microneedles (200 µm long, base diameter 20 µm). 
It is speculated that, besides particle size, other factors, such 
as materials used to prepare the nanoparticles, surface charge 
of the nanoparticles, and the strain and source of animals used 
to harvest skin all contributed to different observations in the 
different studies.
Finally, in the present study, for easy detection, diffusion 
of the fluorescein-labeled nanoparticles through the skin and 
into the receiver compartment was measured. Figure 3 clearly 
shows that the ovalbumin nanoparticles diffused into the 
receiver compartment. We are aware that, for transcutaneous 
immunization, one expects to target the antigen inside the 
skin, particularly the epidermis, not necessarily to deliver 
the antigen through the skin because the skin epidermis has 
abundant antigen-presenting cells.36
As shown in Figure 4A, both ovalbumin in solution or 
ovalbumin nanoparticles failed to induce an antiovalbumin 
immunoglobulin G response when applied to intact mouse 
skin with hair trimmed. However, pretreatment using the International Journal of Nanomedicine 2011:6
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Figure 4 (A) serum antiovalbumin immunoglobulin g induced by ovalbumin or ovalbumin nanoparticles applied onto a skin area treated or not treated with a microneedle 
roller (1000 µm long, base diameter 80 µm). (B) Antiovalbumin immunoglobulin g induced by ovalbumin nanoparticles applied onto a skin area treated with different 
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microneedle roller with large microneedles (1000 µm 
long, base diameter 80 µm) allowed both ovalbumin alone 
and ovalbumin nanoparticles to induce an antiovalbumin 
immunoglobulin G response (Figure 4A). Importantly, the 
antiovalbumin immunoglobulin G level in mice that received 
the ovalbumin nanoparticles was significantly higher than 
that in mice that received ovalbumin alone (Figure 4A), 
demonstrating that, when dosed onto a mouse skin area 
pretreated with microneedles, formulating a protein antigen 
into nanoparticles can enhance its immunogenicity.
Bal et al showed that microneedle-mediated delivery of 
diphtheria toxoid incorporated into N-trimethyl chitosan nano-
particles did not induce a stronger antibody response than the 
diphtheria toxoid alone.25 Therefore, it does not appear that 
formulating any protein antigen in any nanoparticles will be 
beneficial. Many factors, including the physical, chemical, and 
immunological properties of the nanoparticles, the antigen 
itself, and the dimension of the microneedles, may be respon-
sible for the disagreement observed. Interestingly, Bal et al 
actually reported that when diphtheria toxoid was physically 
mixed with the N-trimethyl chitosan nanoparticles and applied 
onto mouse skin pretreated with microneedles, it induced a 
stronger antidiphtheria toxoid immune response than diphthe-
ria toxoid alone.25 This observation led the authors to predict 
that conjugation of antigen with polymeric nanoparticles, 
instead of incorporation of antigens inside nanoparticles, could 
be a better option to potentiate further the immune responses 
by microneedle-mediated vaccination.25 Our data in Figure 4A 
appear to support their prediction. Therefore, more research 
on formulating the antigen of interest into the proper nano-
particles is warranted for successful microneedle-mediated 
immunization using antigens carried by nanoparticles.
Figure 4B shows the antiovalbumin immunoglobulin G 
response induced by the ovalbumin nanoparticles applied onto 
a mouse skin area pretreated with different sized microneedle 
rollers. As expected, pretreatment using the roller with large 
microneedles enabled induction of a significantly stronger 
antiovalbumin immunoglobulin G response than using the 
rollers with small and medium microneedles (Figure 4B). 
However, pretreatment using the roller with small micronee-
dles and the roller with medium microneedles did not lead to 
different levels of antiovalbumin immunoglobulin G response 
(Figure 4B). The in vitro diffusion data in Figure 3A show 
that the roller with medium microneedles (500 µm long, base 
diameter 50 µm) allowed significantly more permeation of 
ovalbumin nanoparticles than the roller with small micro-
needles (200 µm long, base diameter 20 µm). It is possible 
that the amounts of ovalbumin nanoparticles that can permeate 
through the micropores created by these two different sized 
microneedles in vivo were not different enough to be detected 
by measuring the resulting antiovalbumin antibody levels. 
Therefore, it is likely that for any specific nanoparticle 
formulation, the optimal dimension of the microneedles to 
be used needs to be identified individually.International Journal of Nanomedicine 2011:6
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Figure 5 The effect of dose of ovalbumin as an antigen on the antibody responses induced by the ovalbumin nanoparticles. shown are antiovalbumin immunoglobulin g when 
the dose of the ovalbumin in the ovalbumin nanoparticles was 10.5 µg per mouse (A) or 70 µg per mouse (B).
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Mice were treated with ovalbumin nanoparticles 
containing 10.5 µg of ovalbumin initially in order to compare 
the antibody responses induced by ovalbumin nanoparticles 
applied onto a skin area pretreated using microneedles with 
the same ovalbumin nanoparticles applied by subcutaneous 
injection. As shown in Figure 5A, antiovalbumin immu-
noglobulin G levels induced by ovalbumin nanoparticles 
given by subcutaneous injection or by transcutaneous 
immunization following microneedle treatment were not 
significantly different (P = 0.38, 100-fold dilution).   Moreover, 
it appeared that the antibody response induced by the oval-
bumin nanoparticles dosed onto a skin area pretreated with 
microneedles was dose-dependent. For example, ovalbumin 
nanoparticles at a dose of 70 µg per mouse applied onto a 
skin area pretreated with the microneedles induced a stronger 
antiovalbumin immunoglobulin G response than at a dose 
of 10.5 µg (Figure 5A). However, when the ovalbumin dose 
was increased from 10.5 µg per mouse to 70 µg per mouse, 
transcutaneous immunization following microneedle treat-
ment induced a weaker antiovalbumin immunoglobulin G 
response than subcutaneous injection (Figure 5B), indicating 
that the antigen dose determines whether transcutaneous 
immunization following microneedle treatment with antigens 
carried by nanoparticles is more effective than subcutane-
ous injection. The dose of 70 µg ovalbumin per mouse was 
initially selected because data from a previous study showed 
that subcutaneous immunization with 70 µg of ovalbumin 
in ovalbumin-conjugated nanoparticles induced a strong 
antibody response.29 The ovalbumin dose of 10.5 µg (ie, 15% 
of 70 µg) per mouse was used later because the in vitro data 
in Figure 3A showed that, within 24 hours, only about 15% of 
the ovalbumin nanoparticles permeated through a mouse skin 
area pretreated using the roller with large microneedles. Of 
course it is likely that in vivo, less than 15% of the ovalbumin 
nanoparticles have permeated through the skin treated using 
the same microneedle roller due to factors such as acceler-
ated closure of the micropores and less than ideal permeation 
conditions. Moreover, it is known that microneedle puncture 
is less efficient in vivo than in vitro because of the more 
flexible skin tissue, a nonflat skin surface, the cushioning 
effect of fat and muscle layers.37 Nonetheless, transcutaneous 
immunization with a nanoparticle-based vaccine formulation 
onto a skin area pretreated with microneedles has the poten-
tial to elicit a stronger immune response than that achieved 
by subcutaneous injection using a hypodermic needle.
Transepidermal water loss was measured to evaluate 
the extent to which treatment with microneedle rollers had 
damaged the integrity of the skin. As shown in Figure 6, 
transepidermal water loss in the treated skin area increased 
significantly, and the roller with larger microneedles led to a 
larger increase in transepidermal water loss immediately after 
treatment using the microneedle rollers.   Transepidermal water 
loss then gradually decreased and reached a level similar to 
that of intact skin within 24 hours when the rollers with 
small and medium microneedles were used (Figure 6), in 
agreement with what was previously reported.5 However, it International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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permeation of live nonpathogenic E. coli DH5α. E. coli 
is a rod-shaped bacterium about 200–500 nm in diameter 
and 2 µm long, which is physically a nanorod particle.38 
As shown in   Figure 7A, live E. coli DH5α bacteria can 
permeate through micropores created by microneedle roll-
ers on the skin, and pretreatment using a roller with larger 
microneedles allowed permeation of more bacteria. It was 
determined that using the present method, the microneedle 
rollers created about 250 pores/cm2 on the treated skin area. 
The area in the Franz diffusion cells was 0.64 cm2, which 
means that the number of bacterial colony forming units 
shown in Figure 7A represent the total number of bacteria 
that permeated through roughly 160 micropores created by 
the microneedle rollers within four hours. Data in Figure 7B 
showed that the micropores created by the microneedles also 
closed rather quickly. Within 3–6 hours of microneedle treat-
ment, the pores became impermeable to E. coli bacteria, in 
agreement with what was previously reported, ie, that skin 
recovers its barrier function 3–4 hours after microneedle 
treatment.39
Data in Figure 7A indicate that the number of E. coli 
bacteria permeating through the single pore created by a 
21 gauge hypodermic needle within four hours was equal 
to the number of E. coli permeating through the micropores 
(about 160) created by the roller with large microneedles 
(1000 µm long, base diameter 80 µm) within the same 
period of time. In other words, one single pore created by 
the 21 gauge hypodermic needle was equivalent to about 
160 micropores created by the roller with large microneedles. 
Clinically, a 21 gauge needle is normally used to withdraw 
blood, and smaller needles are generally used for vaccination. 
It is expected that the risk of bacterial infection associated 
with microneedle treatment is more likely to be less than 
the risk associated with a hypodermic needle injection. 
  Nonetheless, the finding in the present study does underscore 
the need for sterilization of any formulation that is to be 
applied onto a skin area pretreated with microneedles and 
also the need to keep the application area clean prior to and 
after microneedle treatment. Of course, the microneedles per 
se should be pathogen-free as well.
All the aforementioned experiments were carried out 
using C57BL/6 mice and their skin. It is known that human 
skin is significantly thicker than mouse skin. Therefore, any 
findings made in a mouse model will ultimately need to be 
validated in humans. Before transition to humans, porcine 
skin is a good model to predict more accurately what is 
expected in humans because porcine skin is very similar to 
human skin.40
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took a longer period of time, ie, 48 hours, for transepidermal 
water loss on the skin area pretreated using the roller with 
large microneedles (1000 µm long, base diameter 80 µm) to 
reach the intact level (Figure 6).
The kinetics of transepidermal water loss in Figure 6 
confirmed that treatment with microneedles caused physical 
damage, albeit reversible, to the skin, which was previously 
known.5 However, the relevance of this reversible physical 
damage is not well understood. Specifically, it is unknown to 
what extent the micropores created by the microneedles may 
enhance penetration of microbes through the treated skin area, 
considering that microbes, such as bacteria and viruses, exist 
physically as nanoparticles or microparticles in the environ-
ment and on the skin surface. This information is clinically 
relevant because it allows prediction of the potential risk or 
lack of risk of microbial infection associated with treatment 
using microneedles. Recognizing this issue, Donnelly et al 
studied in vitro permeation of radiolabeled microbes through 
porcine skin pretreated with microneedles.34 In their study, 
harvested porcine skin was saturated with bacteria and then 
treated with microneedles to evaluate the extent to which the 
microneedles can carry pre-existing microbes through the 
skin.34 In the present study, an ex vivo system was devised to 
evaluate the extent to which   pre-existing micropores created 
by the microneedles will allow permeation of live bacteria 
through the skin.   Anesthetized mice were treated with the 
microneedle rollers and immediately euthanized to harvest 
the treated skin samples, which were then used to evaluate International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Finally, microneedles have been exploited in various 
ways to deliver vaccine, ie, solid microneedles coated with 
vaccines, dissolvable microneedles with vaccine incorporated 
in the needles, hollow microneedle-based injection, and the 
application of a vaccine formulation onto the skin prior to 
or after the skin area was treated with microneedles. At this 
moment, transcutaneous immunization on a skin area pre-
treated with microneedles has the slight limitation of being 
a two-step procedure. However, it is not impossible that this 
limitation can be overcome by creative engineering in the 
future. Moreover, all the four methods mentioned above 
have their own unique advantages and disadvantages.26 Solid 
microneedles of sufficient strength are commercially avail-
able, and it is economical to mass produce them. However, 
coating of a particular vaccine onto solid microneedles 
involves reformulation to optimize viscosity and protein 
concentration to avoid aggregation.26 The long-term stabil-
ity of a dry-coated microneedle vaccine is likely better than 
for liquid injectables, but the stability of a particular vac-
cine is dependent on refined formulation and appropriate 
packaging.24 In addition to all these issues, immunization 
via a coated solid microneedle is also a multistep process. 
Immunization needs administration of needles, a waiting 
time of 1–2 minutes to allow the coating to dissolve and, 
finally, application of a patch over the treated area. The 
manufacturing of dissolvable microneedles with sufficient 
strength is still a challenge, and laboratory scale production 
of dissolvable microneedles usually involves the melting 
of polymers at a high temperature, which is detrimental to 
protein stability.41 Hollow microneedles for injection suffer 
from concerns about potential clogging, back pressure from 
densely packed skin layers, and aggregation and syringe-
ability for highly concentrated formulations.26 In addition, 
stability of the proteins and leakage issues during storage of 
prefilled hollow microneedles are still of practical concern.26 
Therefore, the perceived inconvenience associated with the 
two-step procedure of transcutaneous immunization prior 
to or after microneedle treatment should not preclude fur-
ther research efforts. Moreover, knowledge gleaned from 
using solid microneedles is always transferable to other 
microneedle systems.
Conclusion
Pretreatment with microneedles allowed skin permeation 
of nanoparticles with antigen protein conjugated onto them. 
Transcutaneous immunization onto a skin area pretreated 
with microneedles with the protein antigen carried by 
nanoparticles induced a stronger antigen-specific antibody 
response than using the protein antigen alone. The antigen 
dose used to immunize the mice determined whether the 
  microneedle-mediated immunization can induce a stronger 
immune response than when the same nanoparticle-based 
vaccine formulation was dosed by subcutaneous injection. 
Damage to the physical integrity of the skin caused by International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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microneedles, although reversible, may permit permeation of 
live bacteria through the skin, but the risk of bacterial infec-
tion associated with microneedles is not expected to be higher 
than that associated with injection using a hypodermic needle. 
With the increasing interest in nanoparticles as a drug delivery 
system, more research on skin permeation of nanoparticles 
prior to or after microneedle treatment is warranted.
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